Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.

What the trial testedas reported · 2024

Not counted

−13%−19% to −6%

Bigger than 2 in 10 for cardiovascular events

As reported

OR 0.87, 95% CI 0.81–0.94

the abstract, start to end

… or GIP/GLP-1 RAs reduced MACE (OR: 0.87; 95% CI: 0.81-0.94; DISCUSSION …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

OR 0.870.81–0.94

GLP-1 receptor agonistsCardiovascular events

1 / 3

2024

2025

2026

this paperpooled itcites it